In This Issue
From the Diagnostic Immunology Laboratories is published by the Immunodeficiencies and Histiocytosis Program, part of the Division of Hematology / Oncology, at Cincinnati Children's Hospital Medical Center.
Sign Up Now
Sign up to get From the Diagnostic Immunology Laboratories semi-annual newsletter via email.
Download the entire Fall 2007 Newsletter.
| In This Issue - Fall 2007 |
|---|
Patient Vignette - Presentation
An 11-year-old boy presented with recurrent deep skin ulcers, which first began at the age of three years. [more...] | |  |
|
Monitoring B-cell Depletion Therapy
In the previous Newsletter, a relatively well-recognized phenomenon of B-cell recovery following rituximab was shown and discussed... [more...] | |  |
|
Down the Pipeline
CD107a: Turning Cytotoxicity Inside-Out
In the last Newsletter, a flow cytometric (FCM) assay to measure cytotoxicity was introduced (granzyme B transfer assay). [more...] | |  |
|
Immunophenotyping 101
Neither CD4 Nor CD8: Double-Negative T Cells.
In the late 1970s, the dichotomy between T-lymphocyte subsets, based on CD4 and CD8 expression was firmly established. [more...] | |  |
|
Patient Vignette - Part 2
The adhesion marker assay is intended to screen for leukocyte adhesion deficiency type 1 (LAD-1). [more...] | |  |
|
Feedback
We would like to hear from our Customers. We invite you to share your questions and comments with us . This can be regarding existing assays, new assays that you might be interested in, the way we report results, other services that we can provide, etc. Feel free to send/fax/email your comments to us (fax: 513-636-3546; email: immunodeficiencies@cchmc.org).
Recruitment
The Immunodeficiency and Histiocytosis Program in the Division of Hematology/Oncology has a variety of research protocols open for recruitment. These protocols share the main feature that they serve to better understand immunologic disease, as it pertains to increased susceptibility to infections, autoimmunity, lymphoproliferation and hemophagocytosis. Our research protocols focus on careful characterization of clinical disease combined with comprehensive immunologic and genetic testing of blood and/or tissues.
